Identification

Summary

Dantron is a drug used to relieve acute and chronic inflammation of the oral cavity and oropharynx.

Generic Name
Dantron
DrugBank Accession Number
DB04816
Background

Withdrawn from the Canadian, US, and UK markets in 1998 due to genotoxicity.

Type
Small Molecule
Groups
Approved, Investigational, Withdrawn
Structure
Thumb
Weight
Average: 240.2109
Monoisotopic: 240.042258744
Chemical Formula
C14H8O4
Synonyms
  • 1,8-dihydroxy-9,10-anthracenedione
  • 1,8-dihydroxy-9,10-anthraquinone
  • 1,8-dihydroxyanthra-9,10-quinone
  • 1,8-Dihydroxyanthrachinon
  • 1,8-Dihydroxyanthraquinone
  • Chrysazin
  • Danthron
  • Dantron
  • Dantrona
  • Dantrone
  • Dantronum

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Dantron.
AclidiniumThe therapeutic efficacy of Dantron can be decreased when used in combination with Aclidinium.
AlfentanilThe therapeutic efficacy of Dantron can be decreased when used in combination with Alfentanil.
AlloinThe risk or severity of adverse effects can be increased when Dantron is combined with Alloin.
AmantadineThe therapeutic efficacy of Dantron can be decreased when used in combination with Amantadine.
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Dantron.
AmiodaroneThe therapeutic efficacy of Dantron can be decreased when used in combination with Amiodarone.
AmitriptylineThe therapeutic efficacy of Dantron can be decreased when used in combination with Amitriptyline.
AmlodipineThe therapeutic efficacy of Dantron can be decreased when used in combination with Amlodipine.
AmobarbitalThe therapeutic efficacy of Dantron can be decreased when used in combination with Amobarbital.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
No interactions found.

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Altan / Antrapurol / Bancon / Duolax / Prugol / Roydan / Scatron D / Zwitsalax
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Doss TabDantron (50 mg / tab) + Docusate sodium (60 mg / tab)TabletOralSmithkline Beecham Pharma Division Of Smithkline Beecham Inc1993-12-311997-12-17Canada flag
PYRALVEX SOLUCION ORALDantron (5 g) + Salicylic acid (1 g)SolutionBuccal; Oral2007-08-08Not applicableColombia flag
Regulex D CapDantron (50 mg / cap) + Docusate sodium (60 mg / cap)CapsuleOralWhitehall Robins Inc.1993-12-311998-07-29Canada flag

Categories

ATC Codes
A06AB53 — Dantron, combinationsA06AB03 — DantronA06AG03 — Dantron, incl. combinations
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as anthraquinones. These are organic compounds containing either anthracene-9,10-quinone, 1,4-anthraquinone, or 1,2-anthraquinone.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Anthracenes
Sub Class
Anthraquinones
Direct Parent
Anthraquinones
Alternative Parents
Aryl ketones / 1-hydroxy-4-unsubstituted benzenoids / 1-hydroxy-2-unsubstituted benzenoids / Vinylogous acids / Organic oxides / Hydrocarbon derivatives
Substituents
1-hydroxy-2-unsubstituted benzenoid / 1-hydroxy-4-unsubstituted benzenoid / 9,10-anthraquinone / Anthraquinone / Aromatic homopolycyclic compound / Aryl ketone / Hydrocarbon derivative / Ketone / Organic oxide / Organic oxygen compound
Molecular Framework
Aromatic homopolycyclic compounds
External Descriptors
dihydroxyanthraquinone (CHEBI:3682) / Anthraquinone type (C10312)
Affected organisms
Not Available

Chemical Identifiers

UNII
Z4XE6IBF3V
CAS number
117-10-2
InChI Key
QBPFLULOKWLNNW-UHFFFAOYSA-N
InChI
InChI=1S/C14H8O4/c15-9-5-1-3-7-11(9)14(18)12-8(13(7)17)4-2-6-10(12)16/h1-6,15-16H
IUPAC Name
1,8-dihydroxy-9,10-dihydroanthracene-9,10-dione
SMILES
OC1=CC=CC2=C1C(=O)C1=C(C=CC=C1O)C2=O

References

General References
Not Available
Human Metabolome Database
HMDB0029752
KEGG Drug
D07107
KEGG Compound
C10312
PubChem Compound
2950
PubChem Substance
46509077
ChemSpider
2845
BindingDB
11316
RxNav
22293
ChEBI
3682
ChEMBL
CHEMBL53418
ZINC
ZINC000003860369
PharmGKB
PA449206
PDBe Ligand
CHZ
Wikipedia
Dantron
PDB Entries
3nsq

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
TabletOral
Tablet, coatedOral
SolutionBuccal; Oral
CapsuleOral
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)193 °CPhysProp
Predicted Properties
PropertyValueSource
Water Solubility0.305 mg/mLALOGPS
logP2.98ALOGPS
logP3.61ChemAxon
logS-2.9ALOGPS
pKa (Strongest Acidic)9.09ChemAxon
pKa (Strongest Basic)-4.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area74.6 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity65.11 m3·mol-1ChemAxon
Polarizability23.19 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.9899
Blood Brain Barrier+0.7514
Caco-2 permeable+0.6963
P-glycoprotein substrateNon-substrate0.5556
P-glycoprotein inhibitor INon-inhibitor0.9605
P-glycoprotein inhibitor IINon-inhibitor0.9419
Renal organic cation transporterNon-inhibitor0.8913
CYP450 2C9 substrateNon-substrate0.7982
CYP450 2D6 substrateNon-substrate0.9168
CYP450 3A4 substrateNon-substrate0.7151
CYP450 1A2 substrateInhibitor0.8918
CYP450 2C9 inhibitorInhibitor0.775
CYP450 2D6 inhibitorNon-inhibitor0.7456
CYP450 2C19 inhibitorNon-inhibitor0.6159
CYP450 3A4 inhibitorNon-inhibitor0.8357
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7605
Ames testAMES toxic0.9261
CarcinogenicityNon-carcinogens0.893
BiodegradationNot ready biodegradable0.7278
Rat acute toxicity2.8601 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9505
hERG inhibition (predictor II)Non-inhibitor0.9192
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (8.11 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-000i-0090000000-f33bba4b2a76f616e555
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-000i-0090000000-debf61aa41c5f09488eb
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-000i-0090000000-0b90944c9e69d24702c5
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-03dr-0290000000-b75bbfaef6b643f8b203
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-03e9-0960000000-51a32afa2b48f66fdc1f

Carriers

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Skupinska K, Zylm M, Misiewicz I, Kasprzycka-Guttman T: Interaction of anthracene and its oxidative derivatives with human serum albumin. Acta Biochim Pol. 2006;53(1):101-12. Epub 2006 Jan 9. [Article]

Drug created at September 11, 2007 20:07 / Updated at June 12, 2021 10:53